Table 1. Characteristics of 20 HIV-1 infected patients included in the study.
| Pat.* | Sex* | Age* | Sub- type | Ongoing NNRTI treatment** | Earlier NNRTI treatment*** | Other ongoing drugs**** | HIV load (copies/ml) | CD4 count (cells/µl) |
| 1 | m | 37 | D | no | EFV (−134), NVP (−6) | no | 17800 | 200 |
| 2 | m | 43 | B | no | no | no | 292000 | 100 |
| 3a | m | 41 | B | no | EFV (−472) | no | 161000 | 10 |
| 3b | ETR (111) | EFV (−585) | DRV/r | 117000 | 10 | |||
| 4 | m | 52 | B | no | no | no | 63000 | 373 |
| 5a | m | 61 | B | EFV (236) | - | LPV/r, T20 | 21800 | 300 |
| 5b | EFV (248) | - | LPV/r, T20 | 47000 | 335 | |||
| 6 | f | 48 | C | no | EFV (−250), NVP (−60) | TDF, FTC, T20 | 6700 | 155 |
| 7 | m | 56 | C | no | EFV (−286) | ATV,TDF,ABC,3TC | 1500000 | 22 |
| 8a | m | 46 | B | NVP (337) | EFV (−418) | ABC, 3TC, TDF | 13100 | 126 |
| 8b | NVP (339) | EFV (−420), | ABC, 3TC, TDF | 3920 | 126 | |||
| 9a | m | 61 | B | no | EFV (−422), NVP (−192) | LPV/r, 3TC, RAL | 8400 | 209 |
| 9b | no | EFV (−448), NVP (−218) | LPV/r, 3TC, RAL | 20000 | 246 | |||
| 10 | m | 49 | B | NVP (262) | EFV (−286) | ABC,3TC,TDF,T20 | 10400 | 662 |
| 11a | f | 49 | A | EFV (180) | - | ABC, 3TC | 2600 | 260 |
| 11b | no | EFV (−308) | no | 12200 | 219 | |||
| 12 | m | 42 | C | no | NVP (−18) | ATV/r, ABC, 3TC | 1100 | 380 |
| 13 | f | 40 | C | no | no | no | 151000 | 9 |
| 14 | m | 53 | B | no | EFV(−172) | no | 100001 | 420 |
| 15 | m | 51 | B | no | EFV (−308) | DRV/r, TDF, FTC | 910000 | 40 |
| 16 | f | 36 | A | no | no | no | 4420 | 303 |
| 17 | f | 42 | D | no | NVP (−19) | ABC, 3TC, ZDV | 1900 | 159 |
| 18 | m | 49 | D | NVP (11) | EFV (−220) | ABC, 3TC, ZDV | 12000 | 345 |
| 19 | m | 49 | B | no | no | no | 29000 | 234 |
| 20 | f | 49 | B | no | EFV (−8) | no | 4700 | 400 |
*Patients were selected due to a failing ART with the exception of patients no 2, 13, 16, 19 who were infected with an NNRTI-resistant strain and a treatment naïve patient no 4 who had the K103R mutation; a and b indicate a first and a second sample; m: male; f: female; age: years;
**Figure within brackets indicate the number of weeks from the start of the last ongoing NNRTI-treatment to the sampling date.
***Figure within brackets indicates the number of weeks from cessation of the prior NNRTI-containing treatment to the sampling date.
****ABC: abacavir; 3TC: lamivudine; FTC: emitricitabine; TDF: tenofovir; ZDV: zidovudine: LPV/r: lopinavir/ritonavir; ATV/r: atazanavir/ritonavir: DRV/r: darunavir/ritonavir; RAL: raltegravir; T20: enfuvirtid.